TCBWFOTC

TC BioPharm (Holdings) plc

Healthcare·Oncology·Phase 3·Motherwell, United Kingdom
OncologyRespiratoryHematologyEndocrinology

TC BioPharm (Holdings) plc (TCBWF): 6 pipeline candidates · 3 upcoming catalysts · 4 clinical trials. Updated within the last hour.

8.6/10

BioSniper Score

4-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health7.9

D/E 1.40 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth9.8

6 candidates

Catalyst Momentum8.0

3 upcoming, next in ~12d

Insider SignalN/A

N/A

A transparent, data-derived signal for TC BioPharm (Holdings) plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$1.2M

Quarterly Burn

Runway

Revenue

Cash Runway vs Catalysts

Upcoming catalyst timeline.

Today~31 mo out
Catalyst within runway

Pipeline (6 candidates)

Upcoming Catalysts (3)

4 clinical trials·CEO: Mr. Bryan Leland Kobel

Frequently asked questions

How many drug candidates are in TC BioPharm (Holdings) plc's pipeline?

TC BioPharm (Holdings) plc (TCBWF) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is TC BioPharm (Holdings) plc's lead drug candidate?

TC BioPharm (Holdings) plc's most advanced tracked candidate is gb06 (Phase 3) for Growth Hormone Deficiency (GHD).

What is TC BioPharm (Holdings) plc's next catalyst?

TC BioPharm (Holdings) plc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase III Clinical Study of the Efficacy and Safety of Polyethylene Glycolized Human Granulocyte S" — expected June 30, 2026.

Who is the CEO of TC BioPharm (Holdings) plc?

Mr. Bryan Leland Kobel is the chief executive officer of TC BioPharm (Holdings) plc (TCBWF).

Get the full picture on TC BioPharm (Holdings) plc

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.